Exelixis: Positive Pancreatic Cancer Data Brings Two Big Catalysts On Deck (NASDAQ:EXEL)
SDI Productions/E+ via Getty Images Exelixis (NASDAQ:EXEL) has made great progress in advancing its drug known as CABOMETYX for the treatment of several types of cancer. It has already been able to receive approval of this drug for the treatment of patients with kidney cancer, liver cancer and thyroid cancer. However, why I believe it…